Andrea Corcoran - 31 Jan 2024 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Financial Officer, Executive Vice President, Legal and Secretary
Signature
/s/ Andrea Corcoran
Issuer symbol
AVIR
Transactions as of
31 Jan 2024
Net transactions value
-$60,915
Form type
4
Filing time
02 Feb 2024, 21:31:35 UTC
Previous filing
02 Feb 2023
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +44,367 +6.9% 686,051 31 Jan 2024 Direct F1, F2
transaction AVIR Common Stock Sale $60,915 -15,843 -2.3% $3.84 670,208 01 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -44,367 -33% $0.000000 88,733 31 Jan 2024 Common Stock 44,367 Direct F1, F4
transaction AVIR Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 31 Jan 2024 Common Stock 200,000 $4.16 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Includes 8,680 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
F3 Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
F4 The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
F5 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.

Remarks:

Chief Financial Officer, Executive Vice President, Legal and Secretary